Parfitian Priority, Gene Therapy, and Disability

Area of Science:

• Bioethics
• Medical Ethics
• Health Economics

Background:

• Gene therapies for severe genetic diseases present significant ethical challenges due to high costs.
• Decisions on gene therapy provision involve balancing treatment benefits against costs and addressing medical needs.
• Prioritarianism, focusing on benefiting those who are worse off, is a key ethical consideration.

Purpose of the Study:

• To explore the application of prioritarianism to gene therapy decision-making.
• To examine how Derek Parfit's version of prioritarianism can be interpreted and practically applied in medical ethics.
• To propose and defend a novel "time-relative" version of priority for gene therapy allocation.

Main Methods:

• Philosophical analysis of prioritarianism, specifically Derek Parfit's account.
• Ethical assessment of applying prioritarian principles to gene therapy.
• Development of a new theoretical framework for time-relative priority in medical ethics.

Main Results:

• Existing ethical frameworks may not fully address the complexities of gene therapy allocation.
• Parfit's prioritarianism offers a valuable lens but requires careful interpretation for practical medical ethics.
• A time-relative approach to priority can potentially refine how gene therapy benefits are distributed over time.

Conclusions:

• Applying prioritarianism to gene therapy requires careful consideration of its impact on future individuals.
• The proposed time-relative priority offers a nuanced approach to ethical decision-making in gene therapy.
• Further research is needed to integrate this theoretical framework into clinical practice and health policy.